Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

753 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients.
Vasseur D, Arbab A, Giudici F, Marzac C, Michiels S, Tagliamento M, Bayle A, Smolenschi C, Sakkal M, Aldea M, Sassi H, Dall'Olio FG, Pata-Merci N, Cotteret S, Fiévet A, Auger N, Friboulet L, Facchinetti F, Géraud A, Ponce S, Hollebecque A, Besse B, Micol JB, Italiano A, Lacroix L, Rouleau E. Vasseur D, et al. Among authors: facchinetti f. NPJ Precis Oncol. 2024 Feb 26;8(1):51. doi: 10.1038/s41698-024-00544-7. NPJ Precis Oncol. 2024. PMID: 38409229 Free PMC article.
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy.
Recondo G, Mahjoubi L, Maillard A, Loriot Y, Bigot L, Facchinetti F, Bahleda R, Gazzah A, Hollebecque A, Mezquita L, Planchard D, Naltet C, Lavaud P, Lacroix L, Richon C, Lovergne AA, De Baere T, Tselikas L, Deas O, Nicotra C, Ngo-Camus M, Frias RL, Solary E, Angevin E, Eggermont A, Olaussen KA, Vassal G, Michiels S, Andre F, Scoazec JY, Massard C, Soria JC, Besse B, Friboulet L. Recondo G, et al. Among authors: facchinetti f. NPJ Precis Oncol. 2020 Sep 8;4:27. doi: 10.1038/s41698-020-00130-7. eCollection 2020. NPJ Precis Oncol. 2020. PMID: 32964129 Free PMC article.
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer.
Facchinetti F, Lacroix L, Mezquita L, Scoazec JY, Loriot Y, Tselikas L, Gazzah A, Rouleau E, Adam J, Michiels S, Massard C, André F, Olaussen KA, Vassal G, Howarth K, Besse B, Soria JC, Friboulet L, Planchard D. Facchinetti F, et al. Eur J Cancer. 2020 Jun;132:211-223. doi: 10.1016/j.ejca.2020.03.025. Epub 2020 May 6. Eur J Cancer. 2020. PMID: 32388065
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, André F, Soria JC, Friboulet L. Facchinetti F, et al. Clin Cancer Res. 2016 Dec 15;22(24):5983-5991. doi: 10.1158/1078-0432.CCR-16-0917. Epub 2016 Jul 11. Clin Cancer Res. 2016. PMID: 27401242 Clinical Trial.
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.
Chen J, Facchinetti F, Braye F, Yurchenko AA, Bigot L, Ponce S, Planchard D, Gazzah A, Nikolaev S, Michiels S, Vasseur D, Lacroix L, Tselikas L, Nobre C, Olaussen KA, Andre F, Scoazec JY, Barlesi F, Soria JC, Loriot Y, Besse B, Friboulet L. Chen J, et al. Among authors: facchinetti f. Ann Oncol. 2022 Apr;33(4):434-444. doi: 10.1016/j.annonc.2022.01.004. Epub 2022 Jan 21. Ann Oncol. 2022. PMID: 35066105 Free article. Clinical Trial.
753 results